Fred Feldman
Chief Tech/Sci/R&D Officer at Teva Spanish Holdco, Inc.
Profile
Fred Feldman is Vice President of Pre-Clinical Research & Development of Bentlry Pharmaceuticals, Inc. and Chief Scientific Officer and Senior Vice President of CPEX Pharmaceuticals, Inc. Previously, he was Vice President of Pre-Clinical R&D at Armour Pharmaceutical and Senior Vice President-Worldwide, Head-Pre-Clinical R&D and Head of Biotechnology for Centeon LLC and Aventis Behring.
Dr. Feldman received a BS degree in Biochemistry from the University of Chicago and a PhD degree in Biochemistry from Purdue University.
Fred Feldman active positions
Companies | Position | Start |
---|---|---|
Teva Spanish Holdco, Inc.
Teva Spanish Holdco, Inc. Pharmaceuticals: MajorHealth Technology Teva Spanish Holdco, Inc. manufactures, markets, and distributes pharmaceutical products. It specializes in offering treatment for cardiovascular, gastrointestinal, infectious, and neurological diseases. The firm was founded in 1974, and is headquartered in Exeter, NH. | Chief Tech/Sci/R&D Officer | 01/10/2005 |
Former positions of Fred Feldman
Companies | Position | End |
---|---|---|
CPEX Pharmaceuticals, Inc.
CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Chief Tech/Sci/R&D Officer | 01/02/2010 |
Centeon LLC | Chief Tech/Sci/R&D Officer | - |
Aventis Behring | Corporate Officer/Principal | - |
Armour Pharmaceutical Co. | Chief Tech/Sci/R&D Officer | - |
Training of Fred Feldman
The University of Chicago | Undergraduate Degree |
Purdue University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
Teva Spanish Holdco, Inc.
Teva Spanish Holdco, Inc. Pharmaceuticals: MajorHealth Technology Teva Spanish Holdco, Inc. manufactures, markets, and distributes pharmaceutical products. It specializes in offering treatment for cardiovascular, gastrointestinal, infectious, and neurological diseases. The firm was founded in 1974, and is headquartered in Exeter, NH. | Health Technology |
CPEX Pharmaceuticals, Inc.
CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Health Technology |
Aventis Behring | Health Technology |
Armour Pharmaceutical Co. | |
Centeon LLC |
- Stock Market
- Insiders
- Fred Feldman